11月24日 - ** 杰富瑞将癌症检测公司Exact Sciences < EXAS.O (link) >的评级从 "买入 "下调至 "持有"；将预测价格从90美元上调至105美元，较该股上次收盘价上涨4.1%。
** 券商认为该股上涨空间有限，因为在医疗设备生产商雅培实验室< ABT.N (link) >以230亿美元进行收购后，该股可能会在交易价格附近交易。 (link)
** 杰富瑞称，收购溢价对 EXAS 股东来说是公平和有吸引力的，分析师预计不会有其他竞购者加入竞争。
** 预计交易将于 2026 年第二季度完成
** 23家券商中有9家将EXAS股票评级为 "买入 "或更高，14家为 "持有"；他们的PT中值为105美元--数据由LSEG编制
** 截至上一交易日收盘，EXAS股价年累计上涨约79.6%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.